Back to search

Peptide record

TPDB09549

Antibacterial Antifungal Hemolysis Toxicity standard
20 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09549
Antibacterial Antifungal Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia Antifungipept CAFPdb dbAMP HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 20-aa standard natural multi-activity (Antibacterial, Antifungal, Hemolysis, and other sources) peptide sequence curated from AntiBP3, Peptipedia, Antifungipept, and other sources, with an available 3D structural model.
Sequence
AKKVFKRLGIGAVLWVLTWG
Physicochemical Analysis
C110H176N28O22
NDCEQHMPSY
GLKV
2242.78
11.73
4
0
12
+4
-3.00
0.750
131.50
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
11000
490.46
1
Residue Composition
number
2
A
1
R
0
N
0
D
0
C
0
E
0
Q
3
G
0
H
1
I
3
L
3
K
0
M
1
F
0
P
0
S
1
T
2
W
0
Y
3
V
Amino Acid Distribution
A: 2 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 3 H: 0 I: 1 L: 3 K: 3 M: 0 F: 1 P: 0 S: 0 T: 1 W: 2 Y: 0 V: 3
Chemical Descriptors
20
C110H176N28O22
2242.78
11.73
+4
-3.00
0.750
Evidence Records 8 records
Evidence 1 Activity

Activity

0% Hemolysis
Toxicity
1.56 µM
Hemolytic Cytotoxic
0% Hemolysis | 1.56 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 2 Activity

Activity

4% Hemolysis
Toxicity
3.125 µM
Hemolytic Cytotoxic
4% Hemolysis | 3.125 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 3 Activity

Activity

12% Hemolysis
Toxicity
6.25 µM
Hemolytic Cytotoxic
12% Hemolysis | 6.25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 4 Activity

Activity

31% Hemolysis
Toxicity
12.5 µM
Hemolytic Cytotoxic
31% Hemolysis | 12.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 5 Activity

Activity

44% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
44% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 6 Activity

Activity

69% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
69% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 7 Activity

Activity

86% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
86% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 8 Hemolysis

Source & Reference

HemoPI PD_Hemolysis
PD_Hemolysis